We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-3.45%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$334M
AUM Growth
-$21.5M
Cap. Flow
+$1.64M
Cap. Flow %
0.49%
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$3.77M
2
IPSC icon
Century Therapeutics
IPSC
+$3.65M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.89M
4
PRQR icon
ProQR Therapeutics
PRQR
+$2.88M
5
RVMD icon
Revolution Medicines
RVMD
+$2.41M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$5.56M
2
ETNB
89bio
ETNB
+$4.13M
3
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$3.65M
4
BHVN icon
Biohaven
BHVN
+$2.51M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETNB
76
DELISTED
89bio
ETNB
– –
-324,173
Closed -$4.13M
FATE icon
77
Fate Therapeutics
FATE
$326M
– –
-550,940
Closed -$5.56M
MGNX icon
78
MacroGenics
MGNX
$257M
– –
-39,879
Closed -$268K
SCYX icon
79
SCYNEXIS
SCYX
$52M
– –
-19,159
Closed -$239K
CBAY
80
DELISTED
Cymabay Therapeutics
CBAY
– –
-171,059
Closed -$1.07M
FSTX
81
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-576,881
Closed -$3.65M
CINC
82
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-48,000
Closed -$590K
PHAS
83
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-321,856
Closed -$9.69K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, DAFNA Capital Management held 83 positions worth $334M, down 6.1% from $355M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2023 filing shows 4 new, 23 increased, 12 reduced and 11 closed positions. Its largest new stake was ProQR Therapeutics: 940,582 shares worth $2M. The largest sale was Fate Therapeutics, an estimated $5.56M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2023 buy was ProQR Therapeutics: 940,582 shares worth $2M.
  • DAFNA Capital Management added most to Cytokinetics in Q1 2023, an estimated $3.77M increase.
  • DAFNA Capital Management's biggest Q1 2023 reduction was Biohaven, cutting an estimated $2.51M.
  • DAFNA Capital Management fully exited Fate Therapeutics in Q1 2023, selling an estimated $5.56M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $334M portfolio in Q1 2023.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q1 2023.
  • DAFNA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $334M.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.